Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis
Pooled result · Hair lossResult — go to the resultRelative risk 3.252 95% CI 1.437–7.358Authors' conclusion
The use of GLP-1 RAs is significantly associated with an increased risk of hair loss.
Study context
- Population
- Patients in randomized controlled trials (RCTs) or prospective nonrandomized interventional studies reporting hair loss after GLP-1 RA therapy; databases searched from inception to August 20, 20259 studies (7 RCTs, 2 non-RCTs)
- Comparison
- GLP-1 RA vs placebo
- GLP-1 RAn = 4,114
- Outcome
- Hair loss
Methodological detailsrandom-effects model
- Random-effects model
Pooled result
As reported in the abstract
Relative risk
3.252
95% CI 1.437–7.358
GLP-1 RAvs Placebo
RR 3.252 (95% CI 1.437–7.358)
Further pooled results
| Outcome | RR (95% CI) | |
|---|---|---|
| Hair loss, RCTs in patients with overweight or obesity | 3.587 (2.100–6.124) | |
| 0.10.31310Relative risk (log scale) |
- Hair loss event rate after GLP-1 RA therapy (single-arm analysis)
- 3.9%
Original publication
Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis. Diabetes Res Clin Pract. Published 18 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →